Equitable Trust’s Exact Sciences EXAS Stock Holding History

Equitable Trust’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2,786	Closed	-$257K	–	312
2019 Q4	$257K	Buy	2,786 +50	+2%	+$4.4K	0.03%	257
2019 Q3	$247K	Buy	+2,736	New	+$312K	0.03%	255

Other funds holding EXAS

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Equitable Trust's EXAS Position: Q1 2020 in Review

Equitable Trust sold out of Exact Sciences (EXAS) in Q1 2020, closing a stake of 2,786 shares — an estimated $257K sold.

Equitable Trust first reported a position in EXAS in Q3 2019 and held it in 2 quarters. The position peaked at $257K in Q4 2019. 475 funds tracked by Wall St. Rank hold EXAS as of Q1 2020.

Equitable Trust reported no remaining Exact Sciences position as of Q1 2020 after selling out during the quarter.
Equitable Trust sold 2,786 Exact Sciences shares in Q1 2020, an estimated $257K.
Equitable Trust first reported a position in Exact Sciences in Q3 2019 and held it in 2 quarters.
Equitable Trust's Exact Sciences position peaked at $257K in Q4 2019.
475 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2020.

Based on Equitable Trust's 13F filing for Q1 2020, filed 21 May 2020.